Context Therapeutics Inc. announced on April 30, 2025, the presentation of preclinical and translational data for its clinical asset, CT-95, a mesothelin x CD3 T cell engager, at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting took place from April 25-30, 2025, in Chicago, IL.
The preclinical data demonstrated a unique binding location of CT-95 on mesothelin and its ability to avoid binding to shed mesothelin. This feature is intended to minimize the impact of shed antigen, which can act as a decoy and neutralize other MSLN-targeting antibodies, thereby potentially improving tumor targeting.
These findings support the clinical strategy to target mesothelin-expressing cancers, including pancreatic, ovarian, and mesothelioma. Context recently dosed the first patient in its Phase 1 clinical trial of CT-95 and expects to share initial clinical data in mid-2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.